Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | IDE | P14735 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637622 | 0.88 | ALDH1A1 (0.48) | ALDH1A1CLK1CCR5SMN1; SMN2IDE | |
| SCHEMBL29765715 | 0.88 | ALDH1A1 (0.48) | ALDH1A1CLK1CCR5SMN1; SMN2IDE | |
| SCHEMBL29765687 | 0.86 | IDE (0.51) | ALDH1A1CLK1CCR5SMN1; SMN2IDE | |
| SCHEMBL16636781 | 0.86 | IDE (0.51) | ALDH1A1CLK1CCR5SMN1; SMN2IDE | |
| SCHEMBL21937296 | 0.84 | ALDH1A1 (0.43) | ALDH1A1CLK1CCR5SMN1; SMN2IDE | |
| SCHEMBL16637496 | 0.81 | CLK1 (0.54) | ALDH1A1CLK1CCR5SMN1; SMN2IDE | |
| SCHEMBL17608720 | 0.80 | IDE (0.46) | ALDH1A1CLK1CCR5IDEMEN1 | |
| SCHEMBL21891469 | 0.79 | NPC1 (0.41) | ALDH1A1CLK1CCR5SMN1; SMN2IDE | |
| SCHEMBL29765938 | 0.75 | KRAS (0.52) | ALDH1A1CLK1CCR5SMN1; SMN2IDE | |
| SCHEMBL16646862 | 0.75 | KRAS (0.52) | ALDH1A1CLK1CCR5SMN1; SMN2IDE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2021-06-24 | — | — | US | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3636639-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| EP-3055290-B1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-10111874-B2 | Combination therapies for treatment of cancer | ARAXES PHARMA LLC (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| EP-3193851-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | Araxes Pharma LLC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3055290-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| WO-2016044772-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188869-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4178/4885CLK1 1850/4885CCR5 3635/4885 |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 2326/4885CLK1 1023/4885CCR5 897/4885 |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4009/4885CLK1 659/4885CCR5 3427/4885 |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4009/4885CLK1 659/4885CCR5 3427/4885 |
| US-10111874-B2 | Combination therapies for treatment of cancer | KRAS, TP53, HRAS | ALDH1A1 1577/4885CLK1 3440/4885CCR5 3299/4885 |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4009/4885CLK1 659/4885CCR5 3427/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4178/4885CLK1 1850/4885CCR5 3635/4885 |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 3675/4885CLK1 1533/4885CCR5 3573/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4178/4885CLK1 1850/4885CCR5 3635/4885 |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | ALDH1A1 1577/4885CLK1 3440/4885CCR5 3299/4885 |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4178/4885CLK1 1850/4885CCR5 3635/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALDH1A1 4178/4885CLK1 1850/4885CCR5 3635/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | ALDH1A1 1577/4885CLK1 3440/4885CCR5 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.